# A Study of EDP-235 in Healthy Subjects

> **NCT05246878** · PHASE1 · COMPLETED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 72 (actual)

## Conditions studied

- SARS CoV 2 Infection

## Interventions

- **DRUG:** EDP-235
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05246878
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-28
- **Primary completion:** 2022-07-20
- **Final completion:** 2022-07-20
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2022-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05246878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05246878, "A Study of EDP-235 in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05246878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*